TICKERNERD
Menu
VRCAVRCAHealthcare · Biotechnology

VRCA Stock Forecast: Verrica Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$3.35
−2.05% on the day

The 7 Wall Street analysts covering Verrica Pharmaceuticals, Inc. hold a median 12-month price target of $13 — +273.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$58.8M
Ticker Nerd rank
79/ 100
Median analyst target
$13
Analysts covering
7
Revenue$5.9M−53.8% y/y
Operating income−$11.4M
Net income−$13.2M
Free cash flow−$9.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.1%
1M
−30.1%
YTD
−59.7%
1Y
−5.1%
From 52W high
−63.2%
From 52W low
+2.1%
$3.28
$9.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VRCA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Verrica Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
79/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Quality
81
Growth
80
Size
79
Issuance
65
Value
61
Momentum
42
Revisions
38
Volatility
21

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (21): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VRCA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VRCA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26VRCAHigh $20Median $13Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $9Median $13High $20

The green dot is the last close — the median target sits +273.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 May 2026HC Wainwright & Co.AssumesBuy$12
18 Dec 2025Brookline CapitalUpgradeBuy—
14 May 2025NeedhamReiteratesHold—
9 Apr 2025NeedhamReiteratesHold—
8 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
12 Mar 2025NeedhamReiteratesHold—
20 Dec 2024NeedhamReiteratesHold—
6 Nov 2024HC Wainwright & Co.DowngradeNeutral—
5 Nov 2024NeedhamReiteratesHold—
5 Nov 2024RBC CapitalDowngradeSector Perform—
21 Oct 2024TD CowenMaintainsBuy—
4 Oct 2024RBC CapitalMaintainsOutperform—
3 Oct 2024NeedhamDowngradeHold—
2 Oct 2024Brookline CapitalDowngradeHold—
15 Aug 2024NeedhamMaintainsBuy—
15 Aug 2024RBC CapitalMaintainsOutperform—
16 May 2024NeedhamReiteratesBuy—
14 May 2024HC Wainwright & Co.MaintainsBuy—
14 May 2024NeedhamMaintainsBuy—
10 Apr 2024NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

VRCA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VRCA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Verrica Pharmaceuticals, Inc. returned −5.1% against +12.4% for the S&P 500, dividends included.

VRCA vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26VRCAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VRCA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Verrica Pharmaceuticals, Inc. (VRCA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.0×

Cheaper than 86% of US stocks

Price / sales
1.9×

Cheaper than 52% of US stocks

Price / book
13.6×

Cheaper than 6% of US stocks

EV / EBITDA
−1.9×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
−53.9%

Higher than 5% of US stocks

Earnings growth (YoY)
−53.8%

Higher than 10% of US stocks

Gross margin
85.0%

Higher than 94% of US stocks

Operating margin
−194.5%

Higher than 11% of US stocks

Net margin
−102.8%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−72.3%

Higher than 17% of US stocks

Return on assets
−44.0%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Verrica Pharmaceuticals, Inc. (VRCA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Verrica Pharmaceuticals, Inc. has a market value of $58.8M and an enterprise value of $49.4M.

  • Revenue in the twelve months to 30 June 2026: $30.3M. The latest quarter shrank 53.9% year on year.

  • Net income over the same four quarters: −$31.2M, a −102.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.67.

  • Free cash flow in the twelve months to 30 June 2026: −$13.3M.

  • Shares outstanding: 17.2M.

  • Trailing P/E: −2.0×; forward P/E: −2.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Verrica Pharmaceuticals, Inc. employs 76 people — $399K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

VRCA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VRCAVerrica Pharmaceuticals, Inc.$58.8M79
XBITXBiotech, Inc.$57.3M33
RNTXRein Therapeutics, Inc.$57.3M40
SPROSpero Therapeutics, Inc.$59.7M85
BOLDBoundless Bio, Inc.$55.3M87
RNXTRenovoRx, Inc.$59.9M45
APLMApollomics, Inc.$60.3M17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Verrica Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VRCA news & analysis

Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility

GlobeNewsWire · 22 Oct 2026positive

Verrica Pharmaceuticals said it met the pre-defined revenue, growth and operational milestones under its credit facility, increasing the maximum commitment by $15 million and unlocking access to the full $27.5 million. The company said the capital can support YCANTH business growth and its global Phase 3 common warts program through topline readouts, the first expected in Q1 2027.

Why it matters — The expanded non-dilutive capital availability may support Verrica’s stated commercial and clinical development plans.

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

GlobeNewsWire · 30 Sept 2026positive

Verrica Pharmaceuticals announced it will present new data analyses of YCANTH at two upcoming dermatology conferences. The analysis indicates YCANTH achieved complete clearance of molluscum contagiosum approximately four times faster than vehicle, regardless of disease duration.

Why it matters — The presentation of new efficacy data for YCANTH at dermatology conferences is relevant to VRCA watchers as it provides additional clinical evidence for its key product.

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

GlobeNewsWire · 10 Sept 2026positive

Verrica Pharmaceuticals announced it will present YCANTH and VP-315 data at two upcoming dermatology conferences. A post-hoc analysis showed YCANTH achieved high rates of complete clearance in molluscum contagiosum patients regardless of disease duration.

Why it matters — Presentation of favorable clinical data at industry conferences could raise visibility of Verrica's product pipeline among dermatology stakeholders and investors.

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

Verrica Pharmaceuticals announced that its President and CEO, Jayson Rieger, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The company is a therapeutics firm developing and commercializing dermatological treatments, including for skin cancers.

Why it matters — A VRCA watcher would care because the company's CEO will present at a major investment conference, offering exposure to investors.

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

GlobeNewsWire · 27 Aug 2026positive

Verrica Pharmaceuticals announced completion of enrollment in COVE-2, the first pivotal Phase 3 trial evaluating YCANTH for the treatment of common warts, with topline data expected in Q1 2027. The company also noted the second pivotal trial (COVE-3) has exceeded 50% of its enrollment target, with topline data expected in mid-2027.

Why it matters — VRCA watchers would care because completion of enrollment in the first pivotal Phase 3 trial moves the common warts program closer to potential regulatory milestones, with topline data anticipated in 2027.

FAQ

Frequently asked questions about VRCA stock

What is the VRCA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Verrica Pharmaceuticals, Inc. have a median 12-month price target of $13, with estimates ranging from $9 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VRCA stock a buy right now?

Of the 7 analysts covering Verrica Pharmaceuticals, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Verrica Pharmaceuticals, Inc. 79 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VRCA?

As at 31 Oct 2026, Verrica Pharmaceuticals, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will VRCA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +273.1% from the last close, and Ticker Nerd's factor model ranks Verrica Pharmaceuticals, Inc. 79 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VRCA stock forecast for 2030?

No analyst covering Verrica Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRCA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $20 over the next 12 months.

How has VRCA stock performed over the past year?

Verrica Pharmaceuticals, Inc. returned -5.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Verrica Pharmaceuticals, Inc. do?

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing and commercializing clinician-administered treatments for skin diseases that require medical intervention.

What is the latest news on VRCA?

The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility". Verrica Pharmaceuticals said it met the pre-defined revenue, growth and operational milestones under its credit facility, increasing the maximum commitment by $15 million and unlocking access to the full $27.5 million. The company said the capital can support YCANTH business growth and its global Phase 3 common warts program through topline readouts, the first expected in Q1 2027.

Company

About Verrica Pharmaceuticals, Inc.

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing and commercializing clinician-administered treatments for skin diseases that require medical intervention. Its current portfolio centers on YCANTH, a drug-device combination containing cantharidin for the treatment of molluscum contagiosum in adults and children, and for common warts. The company is also advancing additional dermatology programs, including VP-315 for dermatologic oncology indications and other cantharidin-based candidates for wart-related conditions. Verrica Pharmaceuticals serves physicians and patients through products designed for office-based use, with an emphasis on conditions that have limited treatment options. Headquartered in West Chester, Pennsylvania, Verrica Pharmaceuticals plays a specialized role in the dermatology market by targeting both viral skin infections and select skin-related oncology applications.

CEO Dr. Jayson M. Rieger M.B.A., Ph.D. · 76 employees · United States · https://www.verrica.com